Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)

Gilead Sciences has reported Current Deferred Revenue for 8 years, with the latest figure at $202.0 million in Q4 2016.

• For the quarter ending Q4 2016, Current Deferred Revenue fell 54.09% year-over-year to $202.0 million; the trailing twelve-month figure through Dec 2016 stood at $202.0 million (down 54.09% YoY), and the FY2016 full-year result was $202.0 million, down 54.09% from the prior year.
• Current Deferred Revenue for Q4 2016 stood at $202.0 million, down from $361.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $529.0 million in Q1 2016, with the low at $93.7 million in Q2 2012.
• Historically, Current Deferred Revenue has averaged $214.2 million across 5 years, with a median of $126.8 million in 2013.
• Annual changes were most pronounced in 2015 — Current Deferred Revenue surged 296.72% — and 2016, when it plunged 54.09%.
• Gilead Sciences' Current Deferred Revenue stood at $103.2 million in 2012, then grew by 7.6% to $111.0 million in 2013, then increased by 20.72% to $134.0 million in 2014, then surged by 228.36% to $440.0 million in 2015, then sank by 54.09% to $202.0 million in 2016.
• The last three Current Deferred Revenue figures came in at $202.0 million (Q4 2016), $361.0 million (Q3 2016), and $345.0 million (Q2 2016), per Business Quant data.